Expertise in
9
conditions

Dr. Guenther Koehne

Hematology | Oncology
Baptist Health Miami Cancer Institute
8900 N Kendall Dr, 
Miami, FL 
Accepting New Patients
Offers Telehealth
39 Years of Experience
Expertise in
9
conditions
Baptist Health Miami Cancer Institute
8900 N Kendall Dr, 
Miami, FL 

Overview

Guenther Koehne is a Hematologist and an Oncologist in Miami, Florida. Dr. Koehne has been practicing medicine for over 39 years is highly rated in 9 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Wilms Tumor, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Koehne is currently accepting new patients.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

Baptist Hospital Of Miami

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Baptist Health Miami Cancer Institute
8900 N Kendall Dr, Miami, FL 33176

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Long-term Follow-up Study of Patients Who Received VOR33
A Long-term Follow-up Study of Patients Who Received VOR33
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Genetic
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Biological, Drug
Study Drugs: VOR33, Mylotarg
Study Phase: Phase 1/Phase 2
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 20, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Busulfan, Melphalan, Fludarabine
Study Phase: Phase 1
A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: WT1 Analog Peptide Vaccine, Sargramostim (GM-CSF), Lenalidomide
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19
Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Other, Biological
Study Drug: Umbilical cord lining stem cells
Study Phase: Phase 1/Phase 2
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-compatible Related or Unrelated Donors in Patients With B-Cell Lymphoid Malignancies
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-compatible Related or Unrelated Donors in Patients With B-Cell Lymphoid Malignancies
Enrollment Status: Withdrawn
Publish Date: November 01, 2023
Intervention Type: Biological
Study Drugs: Hematopoietic Stem Cells from HLA-Compatible Related, Hematopoietic Stem Cells from HLA Unrelated
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies
Enrollment Status: Withdrawn
Publish Date: September 27, 2022
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

55 Total Publications

Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).
Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).
Journal: JCO precision oncology
Published: October 23, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Luis Raez
Hematology | Oncology
Expertise in
13
conditions
Dr. Luis Raez
Hematology | Oncology

Memorial Cancer Institute

12235 Pines Blvd, 
Pembroke Pines, FL 
 (23.9 miles away)
954-869-5708
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Raez is a Hematologist and an Oncologist in Pembroke Pines, Florida. Dr. Raez is highly rated in 13 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Raez is currently accepting new patients.

Expertise in
6
conditions
Dr. Ofelia Alvarez
Hematology | Oncology
Expertise in
6
conditions
Dr. Ofelia Alvarez
Hematology | Oncology

Office

1475 NW 12th Ave Ste C130, 
Miami, FL 
 (10.7 miles away)
305-243-4000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances

Ofelia Alvarez is a Hematologist and an Oncologist in Miami, Florida. Dr. Alvarez has been practicing medicine for over 44 years is highly rated in 6 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Expertise in
25
conditions
Dr. Manmeet Ahluwalia
Oncology
Expertise in
25
conditions
Dr. Manmeet Ahluwalia
Oncology

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (0.1 miles away)
786-345-7208
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Ahluwalia is an Oncologist in Miami, Florida. Dr. Ahluwalia is highly rated in 25 conditions, according to our data. His top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

Frequently Asked Questions about Dr. Guenther Koehne

How do I make an appointment with Dr. Guenther Koehne?

You can book an appointment with Dr. Guenther Koehne by calling their office at 786-345-7208. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Guenther Koehne a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Guenther Koehne is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Guenther Koehne specialize in?

While Dr. Guenther Koehne is a Hematology, they have specific expertise in Multiple Myeloma, Bone Marrow Transplant, and Wilms Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Guenther Koehne participate in research or clinical trials?

Yes. Dr. Guenther Koehne has published 55 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Guenther Koehne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Guenther Koehne accept my insurance?

Dr. Guenther Koehne accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 786-345-7208 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koehne's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile